NCT00990873

Study of Tissue Samples From Patients With Stage I Non-Small Cell Lung Cancer Enrolled on Research Study CALGB-140202

A Validation of the 64-Gene Signature Using Affymetrix-HG_U133A Array in Stage I NSCLC From the CALGB Lung Cancer Study (140202)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: Alliance for Clinical Trials in Oncology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tissue samples from patients with stage I non-small cell lung cancer enrolled on research study CALGB-140202.

Detailed description

OBJECTIVES: * Determine whether the 64-gene signature can accurately predict the prognosis for survival of patients with stage I non-small cell lung cancer (NSCLC). OUTLINE: RNA is purified from tissue samples obtained by the CALGB Lung Cancer Study (CALGB-140202). The RNA samples are used for gene expression analysis using the 64-gene signature and an Affymetrix-HG\_U133A array. Reverse-transcriptase PCR may also be performed on selected samples.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
GENETIC	gene expression analysis
GENETIC	microarray analysis
GENETIC	reverse transcriptase-polymerase chain reaction
OTHER	laboratory biomarker analysis

Timeline

• Start date: 2009-07-01
• Primary completion: 2014-11-01
• Completion: 2014-11-01
• First posted: 2009-10-07
• Last updated: 2016-06-28